Secreted heat shock protein gp96-Ig: Next-generation vaccines for cancer and infectious diseases

Immunologic Research

Volumn 57, Issue 1-3, 2013, Pages 311-325

  Strbo, Natasa ^a   Garcia Soto, Arlene ^a   Schreiber, Taylor H ^a   Podack, Eckhard R ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Gp96; Heat shock proteins; HIV; Immunotherapy; Vaccine

Indexed keywords

CANCER VACCINE; CD103 ANTIGEN; CHEMOKINE RECEPTOR CCR9; GLYCOPROTEIN GP 96; IMMUNOGLOBULIN;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNIZATION; DENDRITIC CELL; DRUG MECHANISM; HUMAN; IMMUNOGENICITY; INFECTION; INFECTION PREVENTION; MUCOSAL IMMUNITY; NEOPLASM; PERITONEUM CELL; PRIORITY JOURNAL; PROTEIN INDUCTION; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; VAGINA MUCOSA;

ANIMALS; ANTIGEN-PRESENTING CELLS; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; MEMBRANE GLYCOPROTEINS; MUCOUS MEMBRANE; NEOPLASMS; VACCINES, SYNTHETIC;

EID: 84891484180     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-013-8468-x     Document Type: Article

References (130)

1. Nover L, Hightower L. Heat shock and development. Introduction. Results Probl Cell Differ. 1991;17:1-4.
2. Welch WJ. How cells respond to stress. Sci Am. 1993;268(5):56-64.
3. Morimoto RI. Regulation of the heat shock transcriptional response: cross talk between a family of heat shock factors, molecular chaperones, and negative regulators. Genes Dev. 1998;12(24):3788-96.
4. Parsell DA, Lindquist S the function of heat-shock proteins in stress tolerance: degradation and reactivation of damaged proteins. Annu Rev Genet. 1993;27:437-96.
5. Hightower LE. Heat shock, stress proteins, chaperones, and proteotoxicity. Cell. 1991;66(2):191-7.
6. Gething MJ, Sambrook J. Protein folding in the cell. Nature. 1992;355(6355):33-45.
7. Lee AS the accumulation of three specific proteins related to glucose-regulated proteins in a temperature-sensitive hamster mutant cell line K12. J Cell Physiol. 1981;106(1):119-25.
8. Koch G, Smith M, Macer D, Webster P, Mortara R. Endoplasmic reticulum contains a common, abundant calcium-binding glycoprotein, endoplasmin. J Cell Sci. 1986;86:217-32.
9. Lewis MJ, Turco SJ, Green M. Structure and assembly of the endoplasmic reticulum. Biosynthetic sorting of endoplasmic reticulum proteins. J Biol Chem. 1985;260(11):6926-31.
10. Srivastava PK, DeLeo AB, Old LJ. Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc Natl Acad Sci U S A. 1986;83(10):3407-11.
11. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science. 1997;278(5335):117-20.
12. Kovalchin JT, Murthy AS, Horattas MC, Guyton DP, Chandawarkar RY. Determinants of efficacy of immunotherapy with tumor-derived heat shock protein gp96. Cancer Immun. 2001;1:7.
13. Palladino MA Jr, Srivastava PK, Oettgen HF, DeLeo AB. Expression of a shared tumor-specific antigen by two chemically induced BALB/c sarcomas. Cancer Res. 1987;47(19):5074-9.
14. Li Z, Srivastava PK. Tumor rejection antigen gp96/grp94 is an ATPase: implications for protein folding and antigen presentation. EMBO J. 1993;12(8):3143-51.
15. Dollins DE, Immormino RM, Gewirth DT. Structure of unliganded GRP94, the endoplasmic reticulum Hsp90. Basis for nucleotide-induced conformational change. J Biol Chem. 2005;280(34):30438-47.
16. Immormino RM, Dollins DE, Shaffer PL, Soldano KL, Walker MA, Gewirth DT. Ligand-induced conformational shift in the N-terminal domain of GRP94, an Hsp90 chaperone. J Biol Chem. 2004;279(44):46162-71.
17. Udono H, Srivastava PK. Heat shock protein 70-associated peptides elicit specific cancer immunity. J Exp Med. 1993;178(4):1391-6.
18. Peng P, Menoret A, Srivastava PK. Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography. J Immunol Methods. 1997;204(1):13-21.
19. Wearsch PA, Nicchitta CV. Interaction of endoplasmic reticulum chaperone GRP94 with peptide substrates is adenine nucleotide-independent. J Biol Chem. 1997;272(8):5152-6.
20. Sastry S, Linderoth N. Molecular mechanisms of peptide loading by the tumor rejection antigen/heat shock chaperone gp96 (GRP94). J Biol Chem. 1999;274(17):12023-35.
21. Linderoth NA, Popowicz A, Sastry S. Identification of the peptide-binding site in the heat shock chaperone/tumor rejection antigen gp96 (Grp94). J Biol Chem. 2000;275(8):5472-7.
22. Linderoth NA, Simon MN, Hainfeld JF, Sastry S. Binding of antigenic peptide to the endoplasmic reticulum-resident protein gp96/GRP94 heat shock chaperone occurs in higher order complexes. Essential role of some aromatic amino acid residues in the peptide-binding site. J Biol Chem. 2001;276(14):11049-54.
23. Linderoth NA, Simon MN, Rodionova NA, Cadene M, Laws WR, Chait BT, et al. Biophysical analysis of the endoplasmic reticulum-resident chaperone/heat shock protein gp96/GRP94 and its complex with peptide antigen. Biochemistry. 2001;40(5):1483-95.
24. Biswas C, Sriram U, Ciric B, Ostrovsky O, Gallucci S, Argon Y the N-terminal fragment of GRP94 is sufficient for peptide presentation via professional antigen-presenting cells. Int Immunol. 2006;18(7):1147-57.
25. Gidalevitz T, Biswas C, Ding H, Schneidman-Duhovny D, Wolfson HJ, Stevens F, et al. Identification of the N-terminal peptide binding site of glucose-regulated protein 94. J Biol Chem. 2004;279(16):16543-52.
26. Ying M, Flatmark T. Binding of the viral immunogenic octapeptide VSV8 to native glucose-regulated protein Grp94 (gp96) and its inhibition by the physiological ligands ATP and Ca2+. FEBS J. 2006;273(3):513-22.
27. Yang Y, Liu B, Dai J, Srivastava PK, Zammit DJ, Lefrancois L, et al. Heat shock protein gp96 is a master chaperone for toll-like receptors and is important in the innate function of macrophages. Immunity. 2007;26(2):215-26.
28. Melnick J, Dul JL, Argon Y. Sequential interaction of the chaperones BiP and GRP94 with immunoglobulin chains in the endoplasmic reticulum. Natures. 1994;370(6488):373-5.
29. Randow F, Seed B. Endoplasmic reticulum chaperone gp96 is required for innate immunity but not cell viability. Nat Cell Biol. 2001;3(10):891-6.
30. Suto R, Srivastava PK. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science. 1995;269(5230):1585-8.
31. Udono H, Srivastava PK. Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70. J Immunol. 1994;152(11):5398- 403.
32. Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immunol. 2000;12(11):1539-46.
33. Bevan MJ, Minor H. antigens introduced on H-2 different stimulating cells cross-react at the cytotoxic T cell level during in vivo priming. J Immunol. 1976;117(6):2233-8.
34. Bevan MJ. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med. 1976;143(5):1283-8.
35. Bevan MJ, Langman RE, Cohn M. H-2 antigen-specific cytotoxic T cells induced by concanavalin A: estimation of their relative frequency. Eur J Immunol. 1976;6(3):150-6. doi: 10.1002/eji.1830060303.
36. Rock KL, Shen L. Cross-presentation: underlying mechanisms and role in immune surveillance. Immunol Rev. 2005;207:166-83. doi: 10.1111/j.0105-2896. 2005.00301.x.
37. Kurotaki T, Tamura Y, Ueda G, Oura J, Kutomi G, Hirohashi Y, et al. Efficient cross-presentation by heat shock protein 90-peptide complex-loaded dendritic cells via an endosomal pathway. J Immunol. 2007;179(3):1803-13.
38. Binder RJ, Harris ML, Menoret A, Srivastava PK. Saturation, competition, and specificity in interaction of heat shock proteins (hsp) gp96, hsp90, and hsp70 with CD11b+ cells. J Immunol. 2000;165(5):2582-7.
39. Arnold-Schild D, Hanau D, Spehner D, Schmid C, Rammensee HG, de la Salle H, et al. Cutting edge: receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells. J Immunol. 1999;162(7):3757-60.
40. Singh-Jasuja H, Toes RE, Spee P, Munz C, Hilf N, Schoenberger SP, et al. Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis. J Exp Med. 2000;191(11):1965-74.
41. Habich C, Baumgart K, Kolb H, Burkart V the receptor for heat shock protein 60 on macrophages is saturable, specific, and distinct from receptors for other heat shock proteins. J Immunol. 2002;168(2):569-76.
42. Binder RJ, Han DK, Srivastava PK. CD91: a receptor for heat shock protein gp96. Nat Immunol. 2000;1(2):151-5.
43. Basu S, Binder RJ, Ramalingam T, Srivastava PK. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity. 2001;14(3):303-13.
44. Binder RJ, Srivastava PK. Essential role of CD91 in re-presentation of gp96-chaperoned peptides. Proc Natl Acad Sci U S A. 2004;101(16):6128-33.
45. Banerjee PP, Vinay DS, Mathew A, Raje M, Parekh V, Prasad DV, et al. Evidence that glycoprotein 96 (B2), a stress protein, functions as a Th2-specific costimulatory molecule. J Immunol. 2002;169(7):3507-18.
46. Berwin B, Delneste Y, Lovingood RV, Post SR, Pizzo SV. SREC-I, a type F scavenger receptor, is an endocytic receptor for calreticulin. J Biol Chem. 2004;279(49):51250-7.
47. Calderwood SK, Mambula SS, Gray PJ Jr. Extracellular heat shock proteins in cell signaling and immunity. Ann N Y Acad Sci. 2007;1113:28-39.
48. Singh-Jasuja H, Hilf N, Scherer HU, Arnold-Schild D, Rammensee HG, Toes RE, et al the heat shock protein gp96: a receptor-targeted cross-priming carrier and activator of dendritic cells. Cell Stress Chaperones. 2000;5(5):462-70.
49. Singh-Jasuja H, Scherer HU, Hilf N, Arnold-Schild D, Rammensee HG, Toes RE, et al the heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor. Eur J Immunol. 2000;30(8):2211-5.
50. Asea A, Rehli M, Kabingu E, Boch JA, Bare O, Auron PE, et al. Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J Biol Chem. 2002;277(17):15028-34.
51. Vabulas RM, Braedel S, Hilf N, Singh-Jasuja H, Herter S, Ahmad-Nejad P, et al the endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway. J Biol Chem. 2002;277(23):20847-53.
52. Watts C. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu Rev Immunol. 1997;15:821-50. doi: 10.1146/annurev.immunol. 15.1.821.
53. Kato Y, Kajiwara C, Ishige I, Mizukami S, Yamazaki C, Eikawa S, et al. HSP70 and HSP90 differentially regulate translocation of extracellular antigen to the cytosol for cross-presentation. Autoimmune Dis. 2012;2012:745962. doi: 10.1155/2012/745962.
54. Binder RJ, Blachere NE, Srivastava PK. Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatibility complex I molecules. J Biol Chem. 2001;276(20):17163-71.
55. Matsutake T, Sawamura T, Srivastava PK. High efficiency CD91- and LOX-1-mediated re-presentation of gp96-chaperoned peptides by MHC II molecules. Cancer Immun. 2010;10:7.
56. Ishii T, Udono H, Yamano T, Ohta H, Uenaka A, Ono T, et al. Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96. J Immunol. 1999;162(3):1303-9.
57. Li C, Buckwalter MR, Basu S, Garg M, Chang J, Srivastava PK. Dendritic cells sequester antigenic epitopes for prolonged periods in the absence of antigen-encoding genetic information. Proc Natl Acad Sci U S A. 2012;109(43):17543-8. doi: 10.1073/pnas.1205867109.
58. Panjwani NN, Popova L, Srivastava PK. Heat shock proteins gp96 and hsp70 activate the release of nitric oxide by APCs. J Immunol. 2002;168(6):2997-3003.
59. Lehner T, Bergmeier LA, Wang Y, Tao L, Sing M, Spallek R, et al. Heat shock proteins generate beta-chemokines which function as innate adjuvants enhancing adaptive immunity. Eur J Immunol. 2000;30(2):594-603.
60. Chen W, Syldath U, Bellmann K, Burkart V, Kolb H. Human 60-kDa heat-shock protein: a danger signal to the innate immune system. J Immunol. 1999;162(6):3212-9.
61. Binder RJ, Anderson KM, Basu S, Srivastava PK. Cutting edge: heat shock protein gp96 induces maturation and migration of CD11c+ cells in vivo. J Immunol. 2000;165(11):6029-35.
62. Yamazaki K, Nguyen T, Podack ER. Cutting edge: tumor secreted heat shock-fusion protein elicits CD8 cells for rejection. J Immunol. 1999;163(10):5178-82.
63. Strbo N, Vaccari M, Pahwa S, Kolber MA, Fisher E, Gonzalez L, et al. Gp96 SIV Ig immunization induces potent polyepitope specific, multifunctional memory responses in rectal and vaginal mucosa. Vaccine. 2011;29(14):2619-25. doi: 10.1016/j.vaccine.2011.01.044.
64. Strbo N, Vaccari M, Pahwa S, Kolber MA, Doster MN, Fisher E, et al. Cutting edge: novel vaccination modality provides significant protection against mucosal infection by highly pathogenic simian immunodeficiency virus. J Immunol. 2013;190(6):2495-9. doi: 10.4049/jimmunol.1202655.
65. Oizumi S, Strbo N, Pahwa S, Deyev V, Podack ER. Molecular and cellular requirements for enhanced antigen cross-presentation to CD8 cytotoxic T lymphocytes. J Immunol. 2007;179(4):2310-7.
66. Strbo N, Podack ER. Secreted heat shock protein gp96-Ig: an innovative vaccine approach. Am J Reprod Immunol. 2008;59(5):407-16. doi: 10.1111/j.1600-0897.2008.00594.x.
67. Oizumi S, Deyev V, Yamazaki K, Schreiber T, Strbo N, Rosenblatt J, et al. Surmounting tumor-induced immune suppression by frequent vaccination or immunization in the absence of B cells. J Immunother. 2008;31(4):394-401. doi: 10.1097/CJI.0b013e31816bc74d.
68. Strbo N, Oizumi S, Sotosek-Tokmadzic V, Podack ER. Perforin is required for innate and adaptive immunity induced by heat shock protein gp96. Immunity. 2003;18(3):381-90.
69. Masopust D, Vezys V, Wherry EJ, Barber DL, Ahmed R. Cutting edge: gut microenvironment promotes differentiation of a unique memory CD8 T cell population. J Immunol. 2006;176(4):2079-83.
70. Akondy RS, Monson ND, Miller JD, Edupuganti S, Teuwen D, Wu H, et al the yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol. 2009;183(12):7919-30. doi: 10.4049/jimmunol.0803903.
71. Ahmed R, Bevan MJ, Reiner SL, Fearon DT the precursors of memory: models and controversies. Nat Rev Immunol. 2009;9(9):662-8. doi: 10.1038/nri2619.
72. Lefrancois L. Development, trafficking, and function of memory T-cell subsets. Immunol Rev. 2006;211:93-103. doi: 10.1111/j.0105-2896.2006.00393.x.
73. Wakim LM, Waithman J, van Rooijen N, Heath WR, Carbone FR. Dendritic cell-induced memory T cell activation in nonlymphoid tissues. Science. 2008;319(5860):198-202. doi: 10.1126/science.1151869.
74. Picker LJ, Reed-Inderbitzin EF, Hagen SI, Edgar JB, Hansen SG, Legasse A, et al. IL-15 induces CD4 effector memory T cell production and tissue emigration in nonhuman primates. J Clin Invest. 2006;116(6):1514-24. doi: 10.1172/JCI27564.
75. Strbo N, Pahwa S, Kolber MA, Gonzalez L, Fisher E, Podack ER. Cell-secreted Gp96-Ig-peptide complexes induce lamina propria and intraepithelial CD8+ cytotoxic T lymphocytes in the intestinal mucosa. Mucosal Immunol. 2010;3(2):182-92. doi: 10.1038/mi.2009.127.
76. Masopust D. Developing an HIV cytotoxic T-lymphocyte vaccine: issues of CD8 T-cell quantity, quality and location. J Intern Med. 2009;265(1):125-37. doi: 10.1111/j.1365-2796.2008.02054.x.
77. Li Q, Skinner PJ, Ha SJ, Duan L, Mattila TL, Hage A, et al. Visualizing antigen-specific and infected cells in situ predicts outcomes in early viral infection. Science. 2009;323(5922):1726-9. doi: 10.1126/science.1168676.
78. Johansson-Lindbom B, Svensson M, Pabst O, Palmqvist C, Marquez G, Forster R, et al. Functional specialization of gut CD103+ dendritic cells in the regulation of tissue-selective T cell homing. J Exp Med. 2005;202(8):1063-73. doi: 10.1084/jem.20051100.
79. Coombes JL, Robinson NJ, Maloy KJ, Uhlig HH, Powrie F. Regulatory T cells and intestinal homeostasis. Immunol Rev. 2005;204:184-94. doi: 10.1111/j.0105-2896.2005.00250.x.
80. Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 2006;66(11):5527-36. doi: 10.1158/0008-5472.CAN-05-4128.
81. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991-8. doi: 10.1038/ni1102-991.
82. Cavallo F, De Giovanni C, Nanni P, Forni G, Lollini PL. 2011: the immune hallmarks of cancer. Cancer Immunol Immunother. 2011;60(3):319-26. doi: 10.1007/s00262-010-0968-0.
83. Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 2007;13(1):84-8. doi: 10.1038/nm1517.
84. Crane CA, Panner A, Murray JC, Wilson SP, Xu H, Chen L, et al. PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer. Oncogene. 2009;28(2):306-12. doi: 10.1038/onc.2008.384.
85. Schreiber TH, Deyev VV, Rosenblatt JD, Podack ER. Tumor-induced suppression of CTL expansion and subjugation by gp96-Ig vaccination. Cancer Res. 2009;69(5):2026-33. doi: 10.1158/0008-5472.CAN-08-3706.
86. Schreiber TH, Wolf D, Bodero M, Podack E. Tumor antigen specific iTreg accumulate in the tumor microenvironment and suppress therapeutic vaccination. Oncoimmunology. 2012;1(5):642-8. doi: 10.4161/onci.20298.
87. Schreiber TH, Raez L, Rosenblatt JD, Podack ER. Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art. Semin Immunol. 2010;22(3):105-12. doi: 10.1016/j.smim.2010.02.001.
88. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883-92. doi: 10.1056/NEJMoa1113205.
89. Russnes HG, Navin N, Hicks J, Borresen-Dale AL. Insight into the heterogeneity of breast cancer through next-generation sequencing. J Clin Invest. 2011;121(10):3810-8. doi: 10.1172/JCI57088.
90. Srivastava PK, Udono H, Blachere NE, Li Z. Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics. 1994;39(2):93-8.
91. Calderwood SK, Stevenson MA, Murshid A. Heat shock proteins, autoimmunity, and cancer treatment. Autoimmune Dis. 2012;2012:486069. doi: 10.1155/2012/486069.
92. Lv LH, Wan YL, Lin Y, Zhang W, Yang M, Li GL, et al. Anticancer drugs cause release of exosomes with heat shock proteins from human hepatocellular carcinoma cells that elicit effective natural killer cell antitumor responses in vitro. J Biol Chem. 2012;287(19):15874-85. doi: 10.1074/jbc.M112.340588.
93. Todryk SM, Melcher AA, Dalgleish AG, Vile RG. Heat shock proteins refine the danger theory. Immunology. 2000;99(3):334-7.
94. Aguilera R, Saffie C, Tittarelli A, Gonzalez FE, Ramirez M, Reyes D, et al. Heat-shock induction of tumor-derived danger signals mediates rapid monocyte differentiation into clinically effective dendritic cells. Clin Cancer Res. 2011;17(8):2474-83. doi: 10.1158/1078-0432.CCR-10-2384.
95. Li H, Zhou M, Han J, Zhu X, Dong T, Gao GF, et al. Generation of murine CTL by a hepatitis B virus-specific peptide and evaluation of the adjuvant effect of heat shock protein glycoprotein 96 and its terminal fragments. J Immunol. 2005;174(1):195-204.
96. Rapp UK, Kaufmann SH. DNA vaccination with gp96-peptide fusion proteins induces protection against an intracellular bacterial pathogen. Int Immunol. 2004;16(4):597-605.
97. Yan J, Liu X, Wang Y, Jiang X, Liu H, Wang M, et al. Enhancing the potency of HBV DNA vaccines using fusion genes of HBV-specific antigens and the N-terminal fragment of gp96. J Gene Med. 2007;9(2):107-21. doi: 10.1002/jgm.998.
98. Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol. 2002;20:395-425. doi: 10.1146/annurev.immunol.20. 100301.064801.
99. Doody AD, Kovalchin JT, Mihalyo MA, Hagymasi AT, Drake CG, Adler AJ. Glycoprotein 96 can chaperone both MHC class I- and class II-restricted epitopes for in vivo presentation, but selectively primes CD8+ T cell effector function. J Immunol. 2004;172(10):6087-92.
100. Robert J, Ramanayake T, Maniero GD, Morales H, Chida AS. Phylogenetic conservation of glycoprotein 96 ability to interact with CD91 and facilitate antigen cross-presentation. J Immunol. 2008;180(5):3176-82.
101. Daemi A, Bolhassani A, Rafati S, Zahedifard F, Hosseinzadeh S, Doustdari F. Different domains of glycoprotein 96 influence HPV16 E7 DNA vaccine potency via electroporation mediated delivery in tumor mice model. Immunol Lett. 2012;148(2):117-25. doi: 10.1016/j.imlet.2012.10.003.
102. Mohit E, Bolhassani A, Zahedifard F, Taslimi Y, Rafati S the contribution of NT-gp96 as an adjuvant for increasing HPV16 E7-specific immunity in C57BL/6 mouse model. Scand J Immunol. 2012;75(1):27-37. doi: 10.1111/j.1365-3083.2011. 02620.x.
103. Pakravan N, Hassan ZM. Comparison of adjuvant activity of N- and C-terminal domain of gp96 in a Her2-positive breast cancer model. Cell Stress Chaperones. 2011;16(4):449-57. doi: 10.1007/s12192-011-0258-6.
104. Pakravan N, Soleimanjahi H, Hassan ZM. GP96 C-terminal improves Her2/neu DNA vaccine. J Gene Med. 2010;12(4):345-53. doi: 10.1002/jgm.1445.
105. Srivastava PK, Jaikaria NS. Methods of purification of heat shock protein-peptide complexes for use as vaccines against cancers and infectious diseases. Methods Mol Biol. 2001;156:175-86.
106. Gordon NF, Clark BL the challenges of bringing autologous HSP-based vaccines to commercial reality. Methods. 2004;32(1):63-9.
107. Janetzki S, Palla D, Rosenhauer V, Lochs H, Lewis JJ, Srivastava PK. Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. Int J Cancer. 2000;88(2):232-8. doi: 10.1002/1097-0215(20001015)88:2<232:AID-IJC14>3.0.CO;2-8.
108. Mazzaferro V, Coppa J, Carrabba MG, Rivoltini L, Schiavo M, Regalia E, et al. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res. 2003;9(9):3235-45.
109. Rivoltini L, Castelli C, Carrabba M, Mazzaferro V, Pilla L, Huber V, et al. Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells. J Immunol. 2003;171(7):3467-74.
110. Belli F, Testori A, Rivoltini L, Maio M, Andreola G, Sertoli MR, et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol. 2002;20(20):4169-80.
111. Pilla L, Patuzzo R, Rivoltini L, Maio M, Pennacchioli E, Lamaj E, et al. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. Cancer Immunol Immunother. 2006;55(8):958-68. doi: 10.1007/s00262-005-0084-8.
112. Eton O, Ross MI, East MJ, Mansfield PF, Papadopoulos N, Ellerhorst JA, et al. Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma. J Transl Med. 2010;8:9. doi: 10.1186/1479-5876-8-9.
113. Younes A. A phase II study of heat shock protein-peptide complex-96 vaccine therapy in patients with indolent non-Hodgkin's lymphoma. Clin Lymphoma. 2003;4(3):183-5.
114. Oki Y, McLaughlin P, Fayad LE, Pro B, Mansfield PF, Clayman GL, et al. Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. Cancer. 2007;109(1):77-83. doi: 10.1002/cncr.22389.
115. Maki RG, Livingston PO, Lewis JJ, Janetzki S, Klimstra D, Desantis D, et al. A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma. Dig Dis Sci. 2007;52(8):1964-72. doi: 10.1007/s10620-006-9205-2.
116. Testori A, Richards J, Whitman E, Mann GB, Lutzky J, Camacho L, et al. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol. 2008;26(6):955-62. doi: 10.1200/JCO.2007.11.9941.
117. Jonasch E, Wood C, Tamboli P, Pagliaro LC, Tu SM, Kim J, et al. Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. Br J Cancer. 2008;98(8):1336-41. doi: 10.1038/sj.bjc.6604266.
118. Wood C, Srivastava P, Bukowski R, Lacombe L, Gorelov AI, Gorelov S, et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet. 2008;372(9633):145-54. doi: 10.1016/S0140-6736(08)60697-2.
119. Crane CA, Han SJ, Ahn B, Oehlke J, Kivett V, Fedoroff A, et al. Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein. Clin Cancer Res. 2013;19(1):205-14. doi: 10.1158/1078-0432.CCR-11-3358.
120. De Smet C, Lurquin C, De Plaen E, Brasseur F, Zarour H, De Backer O, et al. Genes coding for melanoma antigens recognised by cytolytic T lymphocytes. Eye (Lond). 1997;11(Pt 2):243-8. doi: 10.1038/eye.1997.59.
121. Riley JP, Rosenberg SA, Parkhurst MR. Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase. J Immunother. 2001;24(3):212-20.
122. Singhal S, Miller D, Ramalingam S, Sun SY. Gene expression profiling of non-small cell lung cancer. Lung Cancer. 2008;60(3):313-24. doi: 10.1016/j.lungcan.2008.03.007.
123. Liyanage UK, Goedegebuure PS, Moore TT, Viehl CT, Moo-Young TA, Larson JW, et al. Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma. J Immunother. 2006;29(4):416-24. doi: 10.1097/01.cji.0000205644.43735.4e.
124. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002;169(5):2756-61.
125. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood. 2006;108(3):804-11. doi: 10.1182/blood-2006-02-002774.
126. Precopio ML, Betts MR, Parrino J, Price DA, Gostick E, Ambrozak DR, et al. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med. 2007;204(6):1405-16. doi: 10.1084/jem.20062363.
127. Genesca M, Skinner PJ, Bost KM, Lu D, Wang Y, Rourke TL, et al. Protective attenuated lentivirus immunization induces SIV-specific T cells in the genital tract of rhesus monkeys. Mucosal Immunol. 2008;1(3):219-28. doi: 10.1038/mi.2008.6.
128. Genesca M, Skinner PJ, Hong JJ, Li J, Lu D, McChesney MB, et al. With minimal systemic T-cell expansion, CD8+ T Cells mediate protection of rhesus macaques immunized with attenuated simian-human immunodeficiency virus SHIV89.6 from vaginal challenge with simian immunodeficiency virus. J Virol. 2008;82(22):11181-96. doi: 10.1128/JVI.01433-08.
129. Ramirez SR, Singh-Jasuja H, Warger T, Braedel-Ruoff S, Hilf N, Wiemann K, et al. Glycoprotein 96-activated dendritic cells induce a CD8-biased T cell response. Cell Stress Chaperones. 2005;10(3):221-9.
130. Schreiber TH, Wolf D, Bodero M, Gonzalez L, Podack ER. T cell costimulation by TNFR superfamily (TNFRSF)4 and TNFRSF25 in the context of vaccination. J Immunol. 2012;189(7):3311-8. doi: 10.4049/jimmunol.1200597.